EcoDrugPlus

Neuropeptide Y Receptor Y2

Ensembl ID : ENSLBEG00000003480
Gene Symbol: NPY2R
3 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Type 1-Like

Ensembl ID : ENSLBEG00000018103
Gene Symbol: LOC110002544
3 Cross references
135 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSLBEG00000023591
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSLBEG00000002004
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSLBEG00000001785
Gene Symbol: NTRK2
1 Cross references
207 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSLBEG00000022628
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSLBEG00000019739
Gene Symbol: NTRK2B
1 Cross references
207 Possible Orthologues:

Nicastrin

Ensembl ID : ENSLBEG00000004425
Gene Symbol: NCSTN
4 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSLBEG00000001018
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Non-Receptor Tyrosine-Protein Kinase Tyk2-Like

Ensembl ID : ENSLBEG00000020504
Gene Symbol: LOC109989234
2 Cross references
195 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSLBEG00000026825
Gene Symbol: NOTCH1
3 Cross references
201 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSLBEG00000018512
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).